keyword
MENU ▼
Read by QxMD icon Read
search

HBV DNA

keyword
https://www.readbyqxmd.com/read/28436459/identification-of-pro-inflammatory-cd205-macrophages-in-livers-of-hepatitis-b-virus-transgenic-mice-and-patients-with-chronic-hepatitis-b
#1
Liang Yong, Minmin Li, Yimin Gao, Yanru Deng, Wenbin Liu, Dake Huang, Cuiping Ren, Miao Liu, Jijia Shen, Xin Hou
Hepatic macrophages play a central role in disease pathogenesis during hepatitis B virus (HBV) infection. Our previous study found that CD205(+) macrophages in the liver of hepatitis B surface antigen transgenic (HBs-Tg) mice increased significantly compared with those in wild-type mice, and these increased CD205(+) macrophages were involved in CpG-oligodeoxynucleotide-induced liver injury in HBs-Tg mice. Here, we analysed the phenotype and function of CD205(+) macrophages derived from the liver of HBs-Tg mice and patients with chronic hepatitis B (CHB)...
April 24, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28436380/tenofovir-disoproxil-fumarate-monotherapy-is-superior-to-entecavir-adefovir-combination-therapy-in-patients-with-suboptimal-response-to-lamivudine-adefovir-therapy-for-nucleoside-resistant-hbv-a-96-week-prospective-multicenter-trial
#2
Sae Hwan Lee, Gab Jin Cheon, Hong Soo Kim, Sang Gyune Kim, Young Seok Kim, Soung Won Jeong, Jae Young Jang, Boo Sung Kim, Baek Gyu Jun, Young Don Kim, Dae Won Jun, Joo Hyun Sohn, Tae Yeob Kim, Byung Seok Lee
BACKGROUND: A complete virologic response is closely related to the long-term outcome of patients with chronic hepatitis B and prevention of emerging hepatitis B virus (HBV) mutations. We aimed to evaluate the efficacy of tenofovir disoproxil fumarate (TDF) monotherapy compared to entecavir-adefovir dipivoxil (ETV-ADV) combination therapy in patients with suboptimal responses to long-term lamivudine-adefovir dipivoxil (LAM-ADV) therapy for nucleoside analogue-resistant chronic hepatitis B...
April 24, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28428719/safety-and-efficacy-of-tenofovir-in-chronic-hepatitis-b-related-decompensated-cirrhosis
#3
Soon Kyu Lee, Myeong Jun Song, Seok Hyun Kim, Byung Seok Lee, Tae Hee Lee, Young Woo Kang, Suk Bae Kim, Il Han Song, Hee Bok Chae, Soon Young Ko, Jae Dong Lee
AIM: To evaluate the safety and efficacy of tenofovir disoproxil fumarate (TDF) as a first-line therapy in decompensated liver disease. METHODS: We enrolled 174 chronic hepatitis B-related liver cirrhosis patients treated with 300 mg/d TDF at six Korean centers. Of the 174 cirrhosis patients, 57 were assigned to the decompensated cirrhosis group and 117 were assigned to the compensated cirrhosis group. We followed the patients for 12 mo and evaluated clinical outcomes, including biochemical, virological, and serological responses...
April 7, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28428345/proliferation-of-primary-human-hepatocytes-and-prevention-of-hepatitis-b-virus-reinfection-efficiently-deplete-nuclear-cccdna-in-vivo
#4
Lena Allweiss, Tassilo Volz, Katja Giersch, Janine Kah, Giuseppina Raffa, Joerg Petersen, Ansgar W Lohse, Concetta Beninati, Teresa Pollicino, Stephan Urban, Marc Lütgehetmann, Maura Dandri
OBJECTIVE: The stability of the covalently closed circular DNA (cccDNA) in nuclei of non-dividing hepatocytes represents a key determinant of HBV persistence. Contrarily, studies with animal hepadnaviruses indicated that hepatocyte turnover can reduce cccDNA loads but knowledge on the proliferative capacity of HBV-infected primary human hepatocytes (PHHs) in vivo and the fate of cccDNA in dividing PHHs is still lacking. This study aimed to determine the impact of human hepatocyte division on cccDNA stability in vivo...
April 20, 2017: Gut
https://www.readbyqxmd.com/read/28427875/easl-2017-clinical-practice-guidelines-on-the-management-of-hepatitis-b-virus-infection
#5
Pietro Lampertico, Kosh Agarwal, Thomas Berg, Maria Buti, Harry L A Janssen, George Papatheodoridis, Fabien Zoulim, Frank Tacke
Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors including vaccination policies and migration. This Clinical Practice Guideline presents updated recommendations for the optimal management of HBV infection. Chronic HBV infection can be classified into five phases: (I) HBeAg-positive chronic infection, (II) HBeAg-positive chronic hepatitis, (III) HBeAg-negative chronic infection, (IV) HBeAg-negative chronic hepatitis and (V) HBsAg-negative phase...
April 18, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28427487/the-predictive-value-of-baseline-hbsag-level-and-early-response-for-hbsag-loss-in-patients-with-hbeag-positive-chronic-hepatitis-b-during-pegylated-interferon-alpha-2a-treatment
#6
Ming Hui Li, Lu Zhang, Xiao Jing Qu, Yao Lu, Gei Shen, Zhen Zhen Li, Shu Ling Wu, Ru Yu Liu, Min Chang, Lei Ping Hu, Wen Hao Hua, Shu Jing Song, Gang Wan, Yao Xie
OBJECTIVE: To explore the predictive value of baseline HBsAg level and early response for HBsAg loss in patients with HBeAg-positive chronic hepatitis B during pegylated interferon alpha-2a treatment. METHODS: A total of 121 patients with HBeAg-positive chronic hepatitis B who achieved HBsAg loss were enrolled; all patients were treated with PEG-IFNα-2a 180 μg/week. Serum HBV DNA and serological indicators (HBsAg, anti-HBs, HBeAg, and anti-HBe) were determined before and every 3 months during treatment...
March 2017: Biomedical and Environmental Sciences: BES
https://www.readbyqxmd.com/read/28426876/genome-wide-dna-methylation-analysis-during-non-alcoholic-steatohepatitis-related-multistage-hepatocarcinogenesis-comparison-with-hepatitis-virus-related-carcinogenesis
#7
Junko Kuramoto, Eri Arai, Ying Tian, Nobuaki Funahashi, Masaki Hiramoto, Takao Nammo, Yuichi Nozaki, Yoriko Takahashi, Nanako Ito, Ayako Shibuya, Hidenori Ojima, Aoi Sukeda, Yosuke Seki, Kazunori Kasama, Kazuki Yasuda, Yae Kanai
The aim of this study was to clarify the significance of DNA methylation alterations during non-alcoholic steatohepatitis (NASH)-related hepatocarcinogenesis. Single-CpG-resolution genome-wide DNA methylation analysis was performed on 264 liver tissue samples using the Illumina Infinium HumanMethylation450 BeadChip. After Bonferroni correction, 3331 probes showed significant DNA methylation alterations in 113 samples of non-cancerous liver tissue showing NASH (NASH-N) as compared with 55 samples of normal liver tissue (NLT)...
March 1, 2017: Carcinogenesis
https://www.readbyqxmd.com/read/28426720/a-new-model-mimicking-persistent-hbv-e-antigen-negative-infection-using-covalently-closed-circular-dna-in-immunocompetent-mice
#8
Lei Wang, Min Cao, Qing Lu Wei, Zhong Hua Zhao, Qin Xiang, Hui Juan Wang, Hua Tang Zhang, Guo Qi Lai
Despite the availability of an effective vaccine, hepatitis B virus (HBV) infection remains a major health problem. HBV e antigen (HBeAg)-negative strains have become prevalent. Previously, no animal model mimicked the clinical course of HBeAg-negative HBV infection. To establish an HBeAg-negative HBV infection model, the 3.2-kb full-length genome of HBeAg-negative HBV was cloned from a clinical sample and then circularized to form covalently closed circular (cccDNA). The resulting cccDNA was introduced into the liver of C57BL/6J mice through hydrodynamic injection...
2017: PloS One
https://www.readbyqxmd.com/read/28425405/cost-effectiveness-and-clinical-impact-of-antiviral-strategies-of-hbeag-positive-and-negative-chronic-hepatitis-b
#9
Itziar Oyagüez, María Buti, Max Brosa, Magdalena Rueda, Miguel A Casado
INTRODUCTION: Chronic hepatitis B (CHB) is associated with high burden and healthcare costs. Virologic response achieved with antivirals is associated with progression avoidance. This study aimed to estimate the efficiency and clinical impact of antiviral strategies in CHB patients. MATERIAL AND METHODS: A Markov model estimated lifetime complications and direct costs in both, HBeAg-positive and HBeAg-negative cohorts. Strategy 1 (71% of treated population) and strategy 2 (100%), both based on pegylated interferon (peg-IFN) followed by oral tenofovir or entecavir, were compared to no treatment...
May 2017: Annals of Hepatology
https://www.readbyqxmd.com/read/28422376/spontaneous-remission-of-hepatitis-b-virus-reactivation-during-direct-acting-antiviral-agent-based-therapy-for-chronic-hepatitis-c
#10
Ken Sato, Takeshi Kobayashi, Yuichi Yamazaki, Satoshi Takakusagi, Norio Horiguchi, Satoru Kakizaki, Motoyasu Kusano, Masanobu Yamada
The administration of direct-acting antiviral agents (DAAs) to treat hepatitis C virus (HCV) infection has been reported to cause hepatitis B virus (HBV) reactivation. However, the actual conditions of HBV reactivation and the ideal timing of medical intervention have not been fully evaluated. We reported the cases of two female patients dually infected with HBV and HCV. Both patients were inactive HBV carriers. Although the serum HCV RNA levels promptly decreased after the initiation of DAA-based therapy, the serum HBV DNA levels gradually increased during DAA-based therapy, with the peak serum HBV DNA levels observed at 16 weeks after the initiation of DAA-based therapy in both cases...
April 19, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28418898/plce1-polymorphisms-and-expression-combined-with-serum-afp-level-predicts-survival-of-hbv-related-hepatocellular-carcinoma-patients-after-hepatectomy
#11
Xiwen Liao, Chuangye Han, Wei Qin, Xiaoguang Liu, Long Yu, Guangzhi Zhu, Tingdong Yu, Sicong Lu, Hao Su, Zhen Liu, Zhiwei Chen, Chengkun Yang, Ketuan Huang, Zhengtao Liu, Yu Liang, Jianlu Huang, Jiahong Dong, Lequn Li, Xue Qin, Xinping Ye, Kaiyin Xiao, Minhao Peng, Tao Peng
Polymorphisms in the phospholipase C epsilon (PLCE) 1 gene play a crucial role in the development and progression of several types of cancer. The present study investigated the prognostic significance of PLCE1 gene polymorphisms and expression combined with serum α-fetoprotein (AFP) level in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Single nucleotide polymorphisms were genotyped by sequencing DNA isolated from surgically resected tumor samples of 421 HBV-related HCC patients, and expression profiles were generated based on the GSE14520 dataset...
March 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28418295/phenotypic-and-genotypic-shifts-in-hepatitis-b-virus-in-treatment-naive-patients-taiwan-2008-2012
#12
Chau-Ting Yeh, Kung-Hao Liang, Ming-Ling Chang, Chao-Wei Hsu, Yi-Cheng Chen, Chih-Lang Lin, Wey-Ran Lin, Ming-Wei Lai
We examined the characteristic changes of hepatitis B virus (HBV) in antiviral drug treatment-naive patients referred for pretreatment evaluation in Taiwan during 2008-2012. Over time, we observed substantial decreases in the prevalence of HBV e antigen (HBeAg) and increasing prevalence of the precore G1899A mutation and HBV-DNA levels in HBeAg-positive patients.
May 2017: Emerging Infectious Diseases
https://www.readbyqxmd.com/read/28414577/serum-toll-like-receptor-2-toll-like-receptor-4-levels-in-patients-with-hbeag-negative-chronic-viral-hepatitis-b
#13
Erdem Akbal, Erdem Koçak, Seyfettin Köklü, Bilal Ergül, Ömer Akyürek, Fatma Meriç Yılmaz
Toll-like receptors (TLRs) may play an important role in hepatitis-B pathogenesis. However, serum TLR-2 and TLR-4 levels and their association with serum liver enzymes, hepatitis B virus (HBV) DNA, quantitative HBsAg levels, and liver biopsy findings, are unknown. A total of naive 40 HBeAg (-) chronic hepatitis B (CHB) patients and 20 healthy control subjects were recruited in this study. Liver tests, HBV DNA, serum TLR-2 and TLR-4, and quantitative HBsAg levels were evaluated among all groups. The relationship among TLR-2, TLR-4, quantitative HBsAg levels and liver tests, and liver histological findings were investigated with correlation analysis...
April 17, 2017: Viral Immunology
https://www.readbyqxmd.com/read/28414318/initial-sites-of-hepadnavirus-integration-into-host-genome-in-human-hepatocytes-and-in-the-woodchuck-model-of-hepatitis-b-associated-hepatocellular-carcinoma
#14
R Chauhan, N D Churchill, P M Mulrooney-Cousins, T I Michalak
Hepatitis B virus (HBV) and the closely related woodchuck hepatitis virus (WHV) are potent carcinogens that trigger development of primary hepatocellular carcinoma (HCC). The initial sites of hepadnavirus-host genome integration, their diversity and kinetics of formation can be central to virus persistence and the initiation and progression of HCC. To recognize the nature of the very early virus-host interactions, we explored de novo infection of human hepatocyte-like HepaRG cells with authentic HBV and naive woodchucks with WHV...
April 17, 2017: Oncogenesis
https://www.readbyqxmd.com/read/28408790/hbv-viral-load-and-liver-enzyme-levels-may-be-associated-with-the-wild-mbl2-aa-genotype
#15
Tuane Carolina Ferreira Moura, Ednelza da Silva Graça Amoras, Mauro Sérgio Araújo, Maria Alice Freitas Queiroz, Simone Regina Souza da Silva Conde, Sâmia Demachki, Rosimar Neris Martins-Feitosa, Luiz Fernando Almeida Machado, Izaura Maria Vieira Cayres-Vallinoto, Ricardo Ishak, Antonio Carlos Rosário Vallinoto
The present study investigated the frequencies of rs1800450 (MBL (⁎)B, G>A), rs1800451 (MBL (⁎)C, G>A), and rs5030737 (MBL (⁎)D, C>T) polymorphisms in exon 1 of the MBL2 gene among patients with chronic viral hepatitis. Blood samples from patients infected with hepatitis B virus (HBV; n = 65), hepatitis C virus (HCV; n = 92), and a noninfected control group (n = 300) were investigated. The presence of polymorphisms was detected using a real-time polymerase chain reaction to correlate with liver disease pathogenesis and fibrosis staging according to the Metavir classification...
2017: Mediators of Inflammation
https://www.readbyqxmd.com/read/28407735/telbivudine-treatment-started-in-early-and-middle-pregnancy-completely-blocks-hbv-vertical-transmission
#16
Weihui Sun, Shangfei Zhao, Lei Ma, Anhua Hao, Bo Zhao, Lin Zhou, Fengzhu Li, Mingquan Song
BACKGROUND: To evaluate the efficacy and safety of treating HBV-positive mothers with telbivudine in early and middle pregnancy to prevent mother-to-infant HBV transmission. METHODS: The subject population comprised pregnant women with chronic hepatitis B (CHB; n = 188) from January 2013 to June 2015, with HBV DNA ≥1.0 × 10(7)copies/mL and increased alanine aminotransferase levels. Groups A (n = 62) and B (n = 61) were treated with telbivudine starting at 12 weeks or 20-28 weeks after gestation, respectively...
April 13, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/28407271/a-potent-hbsag-response-in-subjects-with-inactive-hbsag-carrier-treated-with-pegylated-interferon-alpha
#17
Zhenhuan Cao, Yali Liu, Lina Ma, Junfeng Lu, Yi Jin, Shan Ren, Zhimin He, Chengli Shen, Xinyue Chen
BACKGROUND: HBsAg clearance represents a clinical cure although the clearance rate is extremely low. The aim of this study was to evaluate the feasibility and safety profiles of pegylated-interferon α-2a (PEG-IFNα-2a) as a therapeutic option for inactive HBsAg carriers (IHCs). METHODS: 144 IHCs were enrolled and divided into a therapeutic group (102 subjects) and control group (42 subjects). PEG-IFNα-2a and PEG-IFNα-2a combined with Adefovir Dipivoxil (ADV) were used for treatment group subjects with hepatitis B virus (HBV) DNA <20 IU/mL and 20 IU/mL≤HBV DNA<2000 IU/mL, respectively...
April 13, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28404890/perioperative-entecavir-for-patients-with-hbv-related-hepatocellular-carcinoma-and-low-levels-of-viral-dna-analysis-using-propensity-score-matching
#18
Bao-Hong Yuan, Ru-Hong Li, Wei-Ping Yuan, Bang-De Xiang, Ming-Hua Zheng, Tian Yang, Jian-Hong Zhong, Le-Qun Li
The safety and efficacy of perioperative antiviral therapy for patients with hepatitis B virus related hepatocellular carcinoma and low serum levels of hepatitis B virus DNA are unknown. This retrospective study compared serum levels of hepatitis B virus DNA, liver function, morbidity, and length of hospital stay between patients who underwent hepatic resection alone and patients who received entecavir therapy before and after resection (n = 44 in each group). Propensity score matching was used to reduce confounding due to baseline differences between the groups...
February 16, 2017: Oncotarget
https://www.readbyqxmd.com/read/28404133/effect-on-hbs-antigen-clearance-of-addition-of-pegylated-interferon-alfa-2a-to-nucleos-t-ide-analogue-therapy-versus-nucleos-t-ide-analogue-therapy-alone-in-patients-with-hbe-antigen-negative-chronic-hepatitis-b-and-sustained-undetectable-plasma-hepatitis-b
#19
Marc Bourlière, Pascaline Rabiega, Nathalie Ganne-Carrie, Lawrence Serfaty, Patrick Marcellin, Yoann Barthe, Dominique Thabut, Dominique Guyader, Christophe Hezode, Magali Picon, Xavier Causse, Vincent Leroy, Jean Pierre Bronowicki, Patrizia Carrieri, Ghassan Riachi, Isabelle Rosa, Pierre Attali, Jean Michel Molina, Yannick Bacq, Albert Tran, Jean Didier Grangé, Fabien Zoulim, Hélène Fontaine, Laurent Alric, Inga Bertucci, Magali Bouvier-Alias, Fabrice Carrat
BACKGROUND: Findings from uncontrolled studies suggest that addition of pegylated interferon in patients with HBe antigen (HBeAg)-negative chronic hepatitis B receiving nucleos(t)ide analogues with undetectable plasma hepatitis B virus (HBV) DNA might increase HBs antigen (HBsAg) clearance. We aimed to assess this strategy. METHODS: In this randomised, controlled, open-label trial, we enrolled patients aged 18-75 years with HBeAg-negative chronic hepatitis B and documented negative HBV DNA while on stable nucleos(t)ide analogue regimens for at least 1 year from 30 hepatology tertiary care wards in France...
March 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28404092/tenofovir-alafenamide-versus-tenofovir-disoproxil-fumarate-for-the-treatment-of-patients-with-hbeag-negative-chronic-hepatitis-b-virus-infection-a-randomised-double-blind-phase-3-non-inferiority-trial
#20
Maria Buti, Edward Gane, Wai Kay Seto, Henry L Y Chan, Wan-Long Chuang, Tatjana Stepanova, Aric-Josun Hui, Young-Suk Lim, Rajiv Mehta, Harry L A Janssen, Subrat K Acharya, John F Flaherty, Benedetta Massetto, Andrea L Cathcart, Kyungpil Kim, Anuj Gaggar, G Mani Subramanian, John G McHutchison, Calvin Q Pan, Maurizia Brunetto, Namiki Izumi, Patrick Marcellin
BACKGROUND: The novel prodrug tenofovir alafenamide delivers the nucleotide reverse transcriptase inhibitor tenofovir to target cells more efficiently at a lower dose than tenofovir disoproxil fumarate, thereby reducing systemic exposure. We compared the efficacy and safety of the two drugs in patients with HBeAg-negative chronic hepatitis B virus (HBV) infection in a non-inferiority study. METHODS: In this ongoing randomised, double-blind, phase 3, non-inferiority study in 105 centres in 17 countries, patients with HBeAg-negative chronic HBV were randomly assigned (2:1) by a computer-generated allocation sequence (block size six), stratified by plasma HBV DNA concentration and previous treatment status, to receive once-daily oral doses of tenofovir alafenamide 25 mg or tenofovir disoproxil fumarate 300 mg, each with matching placebo...
November 2016: Lancet. Gastroenterology & Hepatology
keyword
keyword
53389
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"